Apr 17 |
ImmunityBio files automatic mixed shelf
|
Mar 6 |
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
|
Mar 5 |
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
|
Feb 27 |
ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise
|
Feb 21 |
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
|
Feb 13 |
ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?
|
Feb 11 |
ImmunityBio: Buy Low Now Vs. Buy High Later
|
Feb 5 |
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
|
Jan 17 |
Shorts are feeling the heat on these ten stocks
|
Jan 2 |
ImmunityBio announces $320M investment by Oberland Capital
|